Back to search
FDAFDA · Food and drugs·Recall number D-0354-2023

Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.

Published March 8, 2023 · Recall initiated: February 17, 2023

Summary

FDA records drug Class III recall D-0354-2023, published March 8, 2023 and initiated February 17, 2023. Recalling firm: Sciegen Pharmaceuticals Inc; Status: Terminated; Reported quantity: 4,392 bottles; Lot: Lot # G177092, Exp. 11/24. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

What to do

Voluntary: Firm initiated · Letter

Get an email if GABAPENTIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GABAPENTIN
Manufacturer
Sciegen Pharmaceuticals Inc
Distributor
Nationwide in the USA and Puerto Rico
UPC
0350228180108
Lot
Lot # G177092, Exp. 11/24
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05. recalled?

Yes. FDA published recall D-0354-2023 on March 8, 2023. Reported hazard: Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GABAPENTIN. UPC: 0350228180108.